ArticleProtein science : a publication of the Protein Society2026
Purification and characterization of recombinant human translation initiation factor eIF3.
Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Purification and characterization of recombinant human translation initiation factor eIF3.Protein science : a publication of the Protein Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Eukaryotic translation initiation factor 3 (eIF3) is an essential factor in protein synthesis. In mammals, it is a ~800 kDa complex composed of 12-13 subunits. Biochemical and mechanistic studies of the function of eIF3 and its individual subunits in translation require purified eIF3. However, current strategies for obtaining mammalian eIF3 rely on purification of the endogenous factor from cultured human cells or rabbit reticulocytes lysates, both of which are expensive and time consuming. Here we present a recombinant insect-cell expression and purification system for human eIF3 which allows the purification of large amounts of functional, homogeneous eIF3 efficiently and cost-effective, while also enabling engineering, such as generation of site-specific mutations in the factor for functional studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.